Exchange: NASDAQ·Updated 01:01 PM EDT

FRNM Freenome, Inc.

$13.21
$2.57
(16.29%)
Today
Mkt Cap$1.7B
Vol192,832.00

About FRNM

Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.
61

Bullish Sentiment

How do you feel about FRNM?

AlertsAndNews
$FRNM Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 "today announced the company will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville."
Rayvio_News_Filter
$FRNM 🏥 Freenome, Inc. announced late-breaking validation data for its updated SimpleScreen CRC blood-based screening test at ACG 2026, showing significant improvement across all subtypes of advanced precancerous lesions and 80.4% sensitivity at 90% specificity for colorectal cancer. Selected from hundreds of headlines

Advertisement|Remove ads.